Walleye Capital
ROIV icon

Walleye Capital’s Roivant Sciences ROIV Stock Holding History

Walleye Capital’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-18,100
Closed -$501K – 5109
2026
Q1 		$501K Sell
18,100
-36,100
-67% -$927K ﹤0.01% 2667
2025
Q4 		$1.18M Buy
54,200
+41,000
+311% +$809K ﹤0.01% 2306
2025
Q3 		$200K Buy
13,200
+4,500
+52% +$55.7K ﹤0.01% 3316
2025
Q2 		$98K Buy
+8,700
New +$94.3K ﹤0.01% 3781
2025
Q1 		– Sell
-5,200
Closed -$61.5K – 5011
2024
Q4 		$61.5K Sell
5,200
-1,600
-24% -$18.9K ﹤0.01% 4303
2024
Q3 		$78.5K Sell
6,800
-32,100
-83% -$365K ﹤0.01% 4496
2024
Q2 		$411K Buy
38,900
+38,800
+38,800% +$425K ﹤0.01% 3672
2024
Q1 		$1.05K Sell
100
-7,400
-99% -$79.8K ﹤0.01% 5317
2023
Q4 		$84.2K Buy
+7,500
New +$73.1K ﹤0.01% 4120

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Walleye Capital's ROIV Position: Q2 2026 in Review

Walleye Capital reduced its Roivant Sciences (ROIV) stake by 36% in Q2 2026, selling an estimated $1.64M and leaving 98,733 shares worth $3.49M. The position accounts for 0.01% of the portfolio, ranked #1063.

Walleye Capital first reported a position in ROIV in Q4 2023 and has held it in 7 quarters since. The position peaked at $5.3M in Q4 2023. 499 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Walleye Capital held 98,733 shares of Roivant Sciences worth $3.49M as of Q2 2026.
  • Walleye Capital sold 55,350 Roivant Sciences shares in Q2 2026, an estimated $1.64M.
  • Roivant Sciences made up 0.01% of Walleye Capital's portfolio in Q2 2026, its #1063 holding.
  • Walleye Capital first reported a position in Roivant Sciences in Q4 2023 and has held it in 7 quarters since.
  • Walleye Capital's Roivant Sciences position peaked at $5.3M in Q4 2023.
  • 499 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.